Log In
Print
BCIQ
Print
Print this Print this
 

Stribild, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (formerly Quad)

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionFixed-dose combination tablet containing 150 mg cobicistat and 150 mg elvitegravir plus Truvada 200 mg emtricitabine/300 mg tenofovir
Molecular Target
Mechanism of ActionHIV integrase inhibitor; HIV reverse transcriptase inhibitor; Cytochrome P450 3A (CYP3A) inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV-1 infected antiretroviral treatment-naïve adults; Treat HIV-1 infection
Regulatory Designation
Partner Japan Tobacco Inc.; Mylan N.V.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

5

$34.3M

$34.3M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today